Biond Biologics Overview
Biond Biologics is a biotechnology company developing immunotherapies and an intracellular drug delivery platform for the treatment of cancer patients. The company uses biologics targeting novel immune evasion mechanisms, discovered through in-house research utilizing real-world patient and tumor samples. Biond Biologics is developing an intracellular delivery platform for biologics (e.g., antibodies or enzymes) inside cells, allowing the company to drug intracellular targets currently considered "undruggable."
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
/PRNewswire/ -- Biond Biologics Ltd. ("Biond" or the "Company"), a private, clinical-stage biopharmaceutical company developing novel immunotherapies for...
Biond Biologics Ltd., a clinical-stage biopharmaceutical company, has launched a Phase 2 study of its novel immunotherapy, BND-22, in combination with anti-PD-1 therapy. The study aims to identify biomarkers related to the mechanism of action and predictive biomarkers for response and resistance in patients with specific cancer types. The study is being conducted in collaboration with MD Anderson Cancer Center and builds on promising results from earlier trials. Biond retains global rights to BND-22 and is focused on advancing it into registrational trials. The company is also developing other innovative therapies targeting novel oncology pathways.
Product StagePartners
growth-positive
Biond Biologics Announces First Patients Dosed with BND-22 (SAR444881) Combinations in Phase 1 Clinical Trial
Biond Biologics has announced that the first patients have been dosed in a phase 1 clinical trial evaluating the safety and anti-tumor activity of BND-22, an ILT2 receptor blocking antibody, in combination with pembrolizumab or cetuximab. The trial aims to explore the potential of BND-22 in treating advanced solid tumors. Biond Biologics entered into an exclusive worldwide license agreement with Sanofi for the development and commercialization of BND-22. The agreement stipulates that Biond will lead the phase 1 study, and Sanofi will assume clinical development and commercialization responsibilities thereafter. BND-22 is a humanized IgG4 antibody that targets the ILT2 receptor and has shown promise in preclinical studies. Biond Biologics is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer.
PartnersInvestment
growth-positive
Biond Biologics Announces Closing of $15 Million Series C Financing
Biond Biologics has closed a $15 million Series C financing round led by Deep Insight, with participation from new investors such as the Heritage Group and existing investors such as Harel Insurance. The financing will enable Biond to bring its next pre-clinical programs to the clinic. Biond has also entered a strategic collaboration with Sanofi for the development of BND-22, its receptor-blocking antibody, and has other innovative immuno-oncology programs in its pipeline. Biond is focused on developing therapies for novel oncology targets and enabling the intracellular delivery of biologics. The companys INspire platform allows for the delivery of drugs to intracellular targets. Deep Insight invests in deep tech companies and sees Bionds platform as having the potential for significant impact.
Investment
growth-positive
Biond Biologics Announces First Patient Dosed in Phase 1 Clinical Trial of BND-22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 Receptor
Biond Biologics has announced the dosing of the first patient in the phase 1 clinical trial of BND-22, an ILT2 receptor blocking antibody for the treatment of advanced solid tumors. The trial will evaluate the safety, tolerability, pharmacokinetics, anti-tumor activity, and exploratory biomarkers of BND-22. The entry of BND-22 into the clinic is a significant milestone for Biond, and the company looks forward to the results of the trial. Biond has an exclusive worldwide license agreement with Sanofi for the development and commercialization of BND-22. Biond is a biopharmaceutical company focused on developing innovative immunotherapies for cancer and a platform for intracellular delivery of biologics.
CustomersPartners
growth-positive
Biond Biologics and Sanofi Enter into Global Licensing Agreement for BND-22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 Receptor
Biond Biologics has entered into an exclusive worldwide license agreement with Sanofi for the development and commercialization of BND-22, a humanized IgG4, antagonist antibody targeting the ILT2 receptor for the treatment of solid tumors. Biond will receive a $125 million upfront payment and could receive over $1 billion in milestones and royalty payments. Biond will lead the phase 1a study of BND-22, and Sanofi will take over clinical development and commercialization. BND-22 has shown a broad anti-tumor effect in preclinical studies and a phase 1 study is planned to start in mid-2021. The partnership with Sanofi validates Bionds strategy and creates value for shareholders.
Partners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $37M |
| Last funding | $15M |
| Stage | C |
| Rounds | 3 |
| Investors | 6 |
Team Members
8
Employees: 11-50
Web & Social Links
| Website | www.biondbio.com |
Locations
Misgav, Israel
Photos & Videos
No files yet
